CLINICALBRIDGE

The 25 GBM trials

The starting point: 25 randomly selected glioblastoma trials, with each trial's machine-checkable eligibility requirements turned into simple yes/no gates. 23 of 25 are resolved to a live ClinicalTrials.gov study (click the NCT ID); the rest are described but not yet matched to a single NCT record.

Trial	Study	Checkable eligibility gates	ClinicalTrials.gov
T1	**FSRT + Atezolizumab (newly dx)**	• Age >= 18 • Diagnosis: GBM • Newly diagnosed • KPS >= 60 (ECOG<=2)	Not resolved to a live NCT ID Unresolved — the previously listed NCT (NCT05423210) is not a findable ClinicalTrials.gov study and no matching trial surfaced on search. FSRT + atezolizumab, newly diagnosed GBM.
T2	**RT VEGF/MMP (observational)**	• Age >= 18 • Diagnosis: GBM • Newly diagnosed • KPS > 60	NCT00083512 · verified Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence
T3	**B7-H3 CAR-T (recurrent)**	• Age >= 18 • Diagnosis: GBM • Recurrent / progressive • Prior RT/chemo: >=4005cGy+TMZ • KPS > 60 • B7H3 positive (IHC) †	NCT04385173 · verified Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma
T4	**Ketogenic diet**	• Age >= 18 • Diagnosis: GBM • KPS >= 70	NCT05708352 · verified A Randomized Controlled Phase 2 Study of the Ketogenic Diet Versus Standard Dietary Guidance for Patients With Newly Diagnosed Glioblastoma in Combination With Standard-of-care Treatment
T5	**Carmustine wafer + retifanlimab**	• Age >= 18 • Age <= 100 • Diagnosis: GBM • Recurrent / progressive • KPS >= 60 • No prior chemo/RT (required)	NCT05083754 · verified A Randomized, Open-label Pilot Trial to Evaluate the Safety and Efficacy of Carmustine Wafer in Combination With Retifanlimab and Standard Radiation With or Without Temozolomide in Newly-Diagnosed Adult Subjects With Glioblastoma
T6	**Anti-PD-1 + SRS (recurrent)**	• Age >= 18 • Diagnosis: GBM • Recurrent / progressive • KPS >= 70 (ECOG0-1)	NCT04977375 · verified Phase Ib/II Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma

Trial	Study	Checkable eligibility gates	ClinicalTrials.gov
T7	**Neuronavigation rs-fMRI**	• Age >= 18 • Diagnosis: GBM / HGG	NCT05864976 · verified Advancing Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning - a Prospective Study
T8	**Sonobiopsy**	• Age >= 18 • Diagnosis: GBM	NCT05281731 · verified Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
T9	**CD70 CAR-T**	• Age >= 18 • Age <= 80 • Diagnosis: GBM • KPS > 70 • CD70 positive (IHC) †	NCT05353530 · verified Phase I Study - To Assess Safety and Feasibility of IL-8 Receptor Modified Patient-derived Activated CD70 CAR T Cell Therapy in CD70+ Adult GBM and Pediatric High-Grade Gliomas (pHGG)
T10	**NEO100 (IDH1-mut, recurrent)**	• Age >= 18 • Diagnosis: HGG • Recurrent / progressive • KPS >= 60 (ECOG0-2/KPS>=60) • IDH: IDH-mutant • Prior RT/chemo: failed prior RT/TMZ	NCT02704858 · verified An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation
T11	**TTFields mapping**	• Age >= 22 • Diagnosis: GBM • Prior RT/chemo: post 6000cGy+TMZ • Willing to use TTFields †	NCT05086497 · verified Whole-Brain Spectroscopy Guided Personalized Mapping of Transducer Arrays for Glioblastoma Patients Receiving Tumor Treating Fields
T12	**PALSUR (palliative vs surgery)**	• Age >= 18 • Age <= 90 • Diagnosis: GBM / HGG	NCT06146738 · verified The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
T13	**RESBIOP (resection vs biopsy)**	• Age >= 18 • Age <= 90 • Diagnosis: GBM / HGG • Newly diagnosed	NCT06146725 · verified The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
T14	**PRESERVE GBM (tissue)**	• Age >= 18 • Diagnosis: GBM • Recurrent / progressive	NCT05756985 · verified Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue (PRESERVE GBM)

Trial	Study	Checkable eligibility gates	ClinicalTrials.gov
T15	**FRONTIER TheraSphere (recurrent)**	• Age >= 18 • Diagnosis: GBM • Recurrent / progressive • KPS >= 60 • Prior RT/chemo: prior RT+TMZ	NCT05303467 · verified FRONTIER: A Feasibility Study to Evaluate the Safety of the TheRaSphere GliOblastoma (GBM) Device iN PaTIEnts With Recurrent GBM
T16	**APG-157 + bevacizumab (recurrent)**	• Age >= 19 • Diagnosis: GBM / HGG • Recurrent / progressive • KPS >= 40 (ECOG0-3) • Prior RT/chemo: prior RT+TMZ • Bevacizumab: progressed on bevacizumab †	NCT06011109 · verified A Pilot Study of APG-157 With Bevacizumab for Patients With Recurrent High-Grade Glioma
T17	**O6-BG/TMZ (newly dx)**	• Age >= 18 • Age <= 75 • Diagnosis: GBM • Newly diagnosed • KPS >= 70 (ECOG0-1/KPS>=70) • MGMT: unmethylated • IDH: IDH-wildtype • No prior chemo/RT (required)	NCT00669669 · verified O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
T18	**GPC3 CAR-T (recurrent)**	• Age >= 21 • Age <= 70 • Diagnosis: GBM • Recurrent / progressive • KPS >= 60 • GPC3 positive (IHC) †	NCT06815432 · verified GPC-3 Chimeric Antigen Receptor T Cells FOR Recurrent GPC-3 Positive Glioblastoma
T19	**Ruxolitinib + RT/TMZ (newly dx)**	• Age >= 18 • Diagnosis: GBM • Newly diagnosed • KPS >= 70 • IDH: IDH-wildtype	NCT06991101 · verified Randomized Phase 2 Trial of Ruxolitinib in Combination With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
T20	**Sonodynamic 5-ALA (recurrent)**	• Age >= 18 • Age <= 80 • Diagnosis: GBM • Recurrent / progressive • KPS >= 70 • Prior RT/chemo: prior chemo/RT • Measurable disease (RANO) †	Not resolved to a live NCT ID Unresolved — the previously listed NCT (NCT06039709) is not a findable ClinicalTrials.gov study and no matching recurrent-GBM sonodynamic trial surfaced on search. 5-ALA + low-intensity focused ultrasound, recurrent GBM.

Trial	Study	Checkable eligibility gates	ClinicalTrials.gov
T21	**Multitracer PET/7T MRI**	• Age >= 18 • Diagnosis: GBM • KPS >= 60	NCT06613841 · verified Pilot Study to Evaluate Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI Methods at 7Tesla Metabolic Profiling of Glioblastoma
T22	**IA bevacizumab (relapsed)**	• Age >= 18 • Diagnosis: GBM • Recurrent / progressive • KPS >= 70 (KPS70/ECOG0-2)	NCT01269853 · verified Phase I/II Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab (Avastin) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma
T23	**RECSUR (recurrent resection)**	• Age >= 18 • Age <= 90 • Diagnosis: GBM • Recurrent / progressive	NCT06283927 · verified The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma: Study Protocol for An International Multicenter Prospective Cohort Study (ENCRAM 2302)
T24	**Loupe fluorescence imaging**	• Age >= 18 • Age <= 90 • Diagnosis: GBM / HGG	NCT04780009 · verified Loupe-Based Intraoperative Fluorescence Imaging for the Guidance of Brain Tumor Surgery
T25	**GLIX1 (recurrent/progressive)**	• Age >= 18 • Diagnosis: GBM / HGG • Recurrent / progressive • KPS >= 70 (ECOG0-1) • <= 2 prior therapy lines	NCT07464925 · verified An Open-Label Phase 1 Safety and Dose Finding Study of Orally Administered GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

† marks a screening criterion the tool treats as “soft” — it can flag it but cannot fully verify it from a records dump (biomarker IHC, measurable disease, prior bevacizumab, stated willingness). Gates are the machine-checkable slice of each trial’s eligibility text; a doctor still confirms the full criteria. Recruiting status and sites are fetched live at run time and are not part of this table.